Russia’s chief oncologist from the Ministry of Health, Andrei Kaprin, announced on his Telegram channel that candidate selection has begun for participation in the clinical study of the oncolytic vaccine “EnteroMix.” “I am pleased to announce the start of prescreening aimed at selecting patients to participate in the first phase of the clinical trial of the oncolytic vaccine ‘EnteroMix,’” Kaprin shared. He explained that patients selected for the trial are those who have previously undergone anti-cancer treatment and have exhausted all available therapy options. The age range for participation is from 18 to 75 years, and the patient’s overall condition must allow for the research to be conducted. Earlier, Russia’s Minister of Health, Mikhail Murashko, stated that other countries have shown interest in the Russian oncolytic vaccine. According to him, specialists will begin using the vaccine in clinical trials by 2025.